Medicine
Cytarabine 100 mg/5 mL injection
Cytarabine 100 mg/5 mL injection is a generic prescription medicine for intrathecal, intravenous, subcutaneous use, made by 4 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 20°C to 25°C (68°F to 77°F) [USP Controlled Room Temperature].
Key facts
- Active ingredient (INN)
- Cytarabine
- Brand
- Sold under the generic name
- Strength
- 100 mg/5 mL
- Dosage form
- Injection
- Route
- Intrathecal, intravenous, subcutaneous
- Packs
- 5 vials of 5 mL and 1 more
- Manufacturers
- Gland PharmaIndiaHospiraMeitheal PharmaceuticalsSagent Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Store at 20°C to 25°C (68°F to 77°F) [USP Controlled Room Temperature].
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01BC01 Cytarabine
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 4 June 1990
- Identifiers
- RxCUI 1731355DailyMed set ID bc2fa221-ea56-48b8-8304-42cd81b8463b, 90f5c7ab-9f15-487d-ba69-ee4107434bcc, 7ab50348-ca78-46a5-aba6-c35b6b21fbfe +1NDC 61703-305, 25021-229, 68083-343 +1Application ANDA071868, ANDA211937, ANDA206189
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
Packs from every labeler of this generic presentation.
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 5 vial, single-dose in 1 carton / 5 mL in 1 vial, single-dose | 68083-343-05 | Gland PharmaIndia | 23 December 2019 |
| 5 vial, single-dose in 1 carton / 5 mL in 1 vial, single-dose | 61703-305-38 | Hospira | 4 June 1990 |
| 5 vial, single-dose in 1 carton / 5 mL in 1 vial, single-dose | 71288-108-06 | Meitheal Pharmaceuticals | 26 June 2020 |
| 5 vial in 1 carton / 5 mL in 1 vial | 25021-229-05 | Sagent Pharmaceuticals | 1 June 2023 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Cytarabine
Clinical summary
Cytarabine is a nucleoside metabolic inhibitor indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It is available as injection for intravenous, subcutaneous and intrathecal use. MedsAcross supplies Cytarabine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about CytarabineFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Cytarabine prescribing information (Hospira) · U.S. National Library of Medicine, DailyMed
Need Cytarabine 100 mg/5 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.